IFNL3 rs8099917: Understanding Your Genetic Response to HCV Therapy
The rs8099917 variant is a genetic marker located near the IFNL3 gene, which plays a significant role in the body's immune response to viral infections. It is primarily studied for its association with how well patients respond to interferon-alpha and ribavirin therapy for chronic hepatitis C.
What each genotype means
Favorable treatment response
This genotype is considered the favorable variant for predicting response to interferon-alpha and ribavirin therapy for hepatitis C. Individuals with this profile have shown a higher likelihood of achieving a sustained virologic response compared to those with G alleles. Please discuss the implications of this genetic marker and your specific treatment plan with your clinician or pharmacist.
The frequency of this genotype varies significantly by ancestry, being more common in European and East Asian populations than in African populations.
Intermediate treatment response
This genotype represents a heterozygous state that is often associated with an intermediate likelihood of responding to interferon-alpha and ribavirin therapy. Research suggests that carrying one G allele may reduce the probability of viral clearance compared to the TT genotype. Please consult your healthcare provider or pharmacist to understand how this may influence your therapeutic options.
This genotype is found across various global populations, with its prevalence reflecting the underlying frequency of the G and T alleles in specific ancestral groups.
Reduced treatment response
This genotype is associated with a lower likelihood of achieving a sustained virologic response when treated with interferon-alpha and ribavirin for hepatitis C. In clinical studies, individuals with this profile have been observed to have higher rates of treatment failure compared to those with the TT genotype. You should discuss this result with your clinician or pharmacist to determine the most appropriate management strategy for your care.
This genotype is more frequently observed in populations of African ancestry compared to European or East Asian cohorts.
What is rs8099917 and Where is it Located?
The rs8099917 variant is a single nucleotide polymorphism (SNP) situated on chromosome 19, specifically in the region upstream of the IFNL3 gene, which is also historically referred to as IL28B. This genomic region is highly significant in pharmacogenomics because it contains several variants that are in linkage disequilibrium, meaning they are often inherited together. Because of this close physical proximity, rs8099917 is frequently studied alongside other markers like rs12979860 to better understand host genetic factors that influence viral clearance. While the SNP itself does not change the protein sequence of IFNL3, its location in the regulatory region suggests it may influence how the gene is expressed or how the surrounding genomic architecture functions during an immune challenge. Researchers use this marker to help stratify patients based on their likelihood of achieving a sustained virologic response when undergoing specific antiviral treatments.
The Role of IFNL3 in Immune Defense
The IFNL3 gene encodes a cytokine known as interferon-lambda 3, which is a critical component of the innate immune system's defense against viruses. Interferons are signaling proteins that help the body establish an 'antiviral state' by triggering the expression of various interferon-stimulated genes that inhibit viral replication. Research indicates that variations in this region can influence the production of interferon-lambda proteins, including the related IFN-lambda 4. Some studies suggest that certain genotypes may lead to a pre-activated state in liver cells, which paradoxically might impair the effectiveness of exogenous interferon-alpha therapy by altering the signaling pathways that the virus relies on. By understanding how these genetic variations modulate the interferon signaling pathway, scientists are gaining deeper insights into why some individuals clear hepatitis C virus infections more effectively than others, both spontaneously and in response to medical intervention.
Research Associations and Evidence Strength
The association between rs8099917 and hepatitis C treatment outcomes is well-documented in clinical literature, particularly for patients infected with HCV genotype 1. Numerous studies have identified the T allele as a favorable marker, often correlating with higher rates of sustained virologic response compared to the G allele. However, the evidence strength is considered limited in a broader clinical context because the predictive power of this SNP can vary significantly depending on the patient's ancestry, the specific viral genotype, and the type of antiviral regimen used. While it was a major focus during the era of interferon-based therapies, its relevance has shifted as newer, highly effective direct-acting antiviral (DAA) treatments have become the standard of care. Consequently, while the association is statistically robust in specific historical cohorts, it is essential to interpret these findings as one of many factors influencing treatment outcomes rather than a definitive diagnostic tool.
Population Frequency and Ancestry
The frequency of the rs8099917 alleles varies significantly across different global populations, which contributes to observed differences in viral clearance rates between ethnic groups. The minor allele frequency generally ranges from approximately 15% in African ancestries to as high as 30-40% in European and East Asian cohorts. This distribution is important because it highlights that genetic markers for treatment response are not uniform worldwide. For instance, higher frequencies of the favorable allele in certain populations have been linked to better spontaneous clearance of the hepatitis C virus. Because these frequencies are ancestry-specific, researchers emphasize the importance of considering genetic background when evaluating the potential impact of this variant on clinical outcomes. Understanding these population-level differences helps clinicians and researchers contextualize why certain groups may show different baseline responses to viral infections and subsequent therapies.
What You Can and Cannot Do With This Information
Genetic information regarding rs8099917 provides insight into biological predispositions but should not be used to make independent medical decisions. If you have received genetic testing results for this variant, it is important to understand that it is only one piece of a complex clinical puzzle. You cannot use this information to diagnose yourself or to predict with absolute certainty how you will respond to any specific medication. Furthermore, because treatment protocols for hepatitis C have evolved significantly with the advent of modern direct-acting antivirals, the clinical utility of this specific SNP has changed. If you are concerned about your treatment options or the implications of your genetic profile, you must discuss these findings with your clinician or a specialized pharmacist. They can provide the necessary context, interpret the results in light of your full medical history, and guide you toward the most appropriate and effective care plan for your specific situation.
How common is this variant?
The minor allele frequency for rs8099917 ranges from approximately 15% in African ancestries to 30-40% in European and East Asian populations.
Frequently asked questions
Is rs8099917 still relevant for modern hepatitis C treatment?
While rs8099917 was highly significant for older interferon-based therapies, its clinical relevance has decreased with the introduction of modern direct-acting antivirals (DAAs), which are highly effective regardless of this genotype.
Does this variant mean I will definitely clear the virus?
No, genetic variants are only one factor in treatment success. Many other variables, including viral load, liver health, and the specific medication regimen, play a much larger role in determining the outcome.
Should I get tested for rs8099917?
Routine testing for this variant is generally not recommended for patients starting modern hepatitis C treatments. You should consult your doctor to determine if any genetic testing is necessary for your specific care plan.
Can I change my genotype?
No, your genotype is determined at conception and cannot be changed. It is a permanent part of your genetic makeup.
Sources & further reading
Educational information only, last refreshed 9/28/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs8099917?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IFNL3
Upstream variant near IFNL3 associated with spontaneous clearance of hepatitis C virus infection and hepatic inflammatory responses.
This variant is a primary predictor of sustained virologic response to interferon-alpha-based therapies in patients with chronic hepatitis C infection.